| Theme |
Hepatitis B : Towards the Elimination |
| Title |
The Incidence of Hepatocellular Carcinoma in Hepatitis B Patients Treated with Nucleos(t)ide Analogues |
| Author |
Tetsuya Hosaka |
Department of Hepatology, Toranomon Hospital |
| [ Summary ] |
Nucleos(t)ide analogues (NAs) are known to reduce hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB) patients, but do not eliminate HCC risk. The serum hepatitis B core‒related antigen (HBcrAg) has been known to be a surrogate marker of intrahepatic covalently closed circular DNA (cccDNA). Patients with high on‒treatment HBcrAg levels were likely to develop HCC despite long‒term NA treatment. |